The acute myeloid leukemia drug Xospata has entered the last gateway to resolving its dosing cycle restrictions.

According to industry sources, Astellas Korea has started drug pricing negotiations with the National Health Insurance Service for its Xospata (gilteritinib), a new drug for patients with relapsed or refractory acute myeloid leukemia (AML) with an FLT3 mutation

If the negotiations are finalized by the deadline, the drug could be covered in the first quarter of next year.

The drug applied for reimbursement extensions in November last year passed the Cancer Disease Review Committee in May, and passed the Drug Reimbursement Evaluation Committee last month.